!Kung,
GZTC press release by cut and paste. Actually, it does seem to be pertinent to the HSA project. Unforturnately for Rman, it doesn't specify who gets to milk the mice.
Aside to Rman: perhaps breast implants in the mice would solve the problems w/ milking them ;-)
biowa
*******************************************
LEIDEN, The Netherlands and FRAMINGHAM, Mass., May 15 /PRNewswire/ -- Pharming B.V. and Genzyme Transgenics Corp. (Nasdaq: GZTC) jointly announced today that they had ended arbitration proceedings filed under a 1994 Cross-License Agreement between the companies. In ending the arbitration, the companies amended the Cross-License Agreement to clarify the terms under which Genzyme Transgenics may work in transgenic cattle, and Pharming may work in transgenic goats, when using the cross-licensed patents.
Under the 1994 Cross-License Agreement, Genzyme Transgenics had granted Pharming a license to patent rights relating to milk-specific promoters for protein production in the milk of mice, rabbits, sheep and cattle. Pharming had granted Genzyme Transgenics a license to patent rights relating to casein promoters for protein production in the milk of mice, rabbits, sheep and goats. The Cross-License Agreement also specified the conditions under which Genzyme Transgenics could produce proteins in the milk of transgenic cattle. Similar conditions applied if Pharming wished to produce proteins in the milk of transgenic goats.
In addition to clarifying the terms under which Genzyme Transgenics and Pharming, respectively, may work in transgenic cattle and goats, the amended Cross-License Agreement clarifies the terms under which Pharming will receive royalties when Genzyme Transgenics produces proteins in transgenic cattle when covered by Pharming's licensed patent; and the terms under which Genzyme Transgenics will receive royalties when Pharming produces proteins in transgenic goats when covered by Genzyme Transgenics' licensed patent. Genzyme Transgenics recently announced that it will produce human serum albumin in transgenic cattle in collaboration with a German medical products company.
The amended Cross-License Agreement further specifies that Genzyme Transgenics and Pharming each have a right of first refusal to perform the work in goats and cattle, respectively, which the other party would seek to contract to a third party. Finally, the amended Cross-License Agreement clarifies that the agreement's conditions and restrictions apply only to the cross-licensed patents, and that no rights other than the cross-licensed patents are conferred on the companies. All other material terms of the original Cross-License Agreement remain in force. |
